Status:
COMPLETED
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
Lead Sponsor:
ViiV Healthcare
Collaborating Sponsors:
Pfizer
Conditions:
HIV
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
Eligibility Criteria
Inclusion
- Asymptomatic HIV-1 infected male and female patients
- Weight between 50 and 100kg and within the permitted range for their height
- Patients with virus that targets CCR5 receptor
Exclusion
- Patients with a CD4 count \<250 cells/mm3 or HIV viral load \<5000 copies/mL
- Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion
- Patients with acquired immunodeficiency syndrome (AIDS) or a previous AIDS diagnosis
- Patients who are taking or have taken antiretroviral drugs in the eight weeks prior to the study screening visit
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2003
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00634959
Start Date
July 1 2003
End Date
December 1 2003
Last Update
November 10 2010
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-2050
2
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
3
Pfizer Investigational Site
Cologne, Germany, 50931
4
Pfizer Investigational Site
Frankfurt, Germany, 60596